The lead drug in Alex­ion’s $930M buy­out deal last fall just flopped — adding in­jury to an­a­lysts’ M&A in­sults

When Alex­ion $ALXN put down $930 mil­lion in cash last fall to buy Achillion, the biotech’s top ex­ecs were par­tic­u­lar­ly proud of 2 clin­i­cal-stage as­sets, with a spot­light on the lead drug dan­i­co­pan (ACH-4471) in Phase II. That drug, along with a com­pan­ion ther­a­py in Phase I, fit right in their R&D wheel­house, not­ed CEO Lud­wig Hantson.

But now the lead drug, re­dubbed ALXN2040, is be­ing washed out and repo­si­tioned af­ter fail­ing 2 Phase II tri­als for C3 Glomeru­lopa­thy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER